Long-read Sequencing of CYP2D6 May Improve Psychotropic Prescribing and Treatment Outcomes: A Systematic Review and Meta-analysis

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2024 Sep 12

PMID 39262167

Authors

Dean Kaptsis

Martin Lewis

Michael Sorich

Malcolm Battersby

Affiliations

Soon will be listed here.

Abstract

Background: The enzyme expression (i.e. phenotype) of the Cytochrome P450 2D6 (CYP2D6) gene is highly relevant to the metabolism of psychotropic medications, and therefore to precision medicine (i.e. personalised prescribing).

Aims: This review aims to assess the improvement in CYP2D6 phenotyping sensitivity (IPS) and accuracy (IPA) offered by long-read sequencing (LRS), a new genetic testing technology.

Methods: Human DNA samples that underwent LRS genotyping of CYP2D6 in published, peer-reviewed clinical research were eligible for inclusion. A systematic literature search was conducted until 30 September 2023. CYP2D6 genotypes were translated into phenotypes using the international consensus method. IPS was the percentage of non-normal LRS CYP2D6 phenotypes undetectable with FDA-approved testing (AmpliChip). IPA was the percentage of LRS CYP2D6 phenotypes mischaracterised by non-LRS genetic tests (for samples with LRS and non-LRS data).

Results: Six studies and 1411 samples were included. In a meta-analysis of four studies, IPS was 10% overall (95% CI = (2, 18); = 1385), 20% amongst Oceanians (95% CI = (17, 23); = 582) and 2% amongst Europeans (95% CI = (1, 4); = 803). IPA was 4% in a large European cohort (95% CI = (2, 7); = 567). When LRS was used selectively (e.g. for novel or complex CYP2D6 genotypes), very high figures were observed for IPS (e.g. 88%; 95% CI = (72, 100); = 17; country = Japan) and IPA (e.g. 76%; 95% CI = (55, 98); = 17; country = Japan).

Conclusions: LRS improves CYP2D6 phenotyping compared to established genetic tests, particularly amongst Oceanian and Japanese individuals, and those with novel or complex genotypes. LRS may therefore assist in optimising personalised prescribing of psychotropic medications. Further research is needed to determine associated clinical benefits, such as increased medication safety and efficacy.

References

Gaedigk A, Casey S, Whirl-Carrillo M, Miller N, Klein T . Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clin Pharmacol Ther. 2021; 110(3):542-545. PMC: 8725060. DOI: 10.1002/cpt.2321. View

Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder J . Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2016; 19(1):69-76. PMC: 5292679. DOI: 10.1038/gim.2016.80. View

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn C, Whaley R . An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021; 110(3):563-572. PMC: 8457105. DOI: 10.1002/cpt.2350. View

Cavallari L, Van Driest S, Prows C, Bishop J, Limdi N, Pratt V . Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med. 2019; 21(10):2255-2263. PMC: 6754805. DOI: 10.1038/s41436-019-0484-3. View

Gaedigk A . Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013; 25(5):534-53. DOI: 10.3109/09540261.2013.825581. View

Bousman C, Stevenson J, Ramsey L, Sangkuhl K, Hicks J, Strawn J . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023; 114(1):51-68. PMC: 10564324. DOI: 10.1002/cpt.2903. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Pratt V, Cavallari L, Del Tredici A, Gaedigk A, Hachad H, Ji Y . Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists.... J Mol Diagn. 2021; 23(9):1047-1064. PMC: 8579245. DOI: 10.1016/j.jmoldx.2021.05.013. View

Bertilsson L, Dahl M, Dalen P, Al-Shurbaji A . Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002; 53(2):111-22. PMC: 1874287. DOI: 10.1046/j.0306-5251.2001.01548.x. View

10.

Lyon E, Gastier Foster J, Palomaki G, Pratt V, Reynolds K, Sabato M . Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet Med. 2012; 14(12):990-1000. DOI: 10.1038/gim.2012.108. View

11.

Bousman C, Bengesser S, Aitchison K, Amare A, Aschauer H, Baune B . Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry. 2020; 54(1):5-17. DOI: 10.1055/a-1288-1061. View

12.

Pearce A, Terrill B, Alffenaar J, Patanwala A, Kummerfeld S, Day R . Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals. Intern Med J. 2022; 52(7):1135-1143. PMC: 9541847. DOI: 10.1111/imj.15719. View

13.

Jameson A, Faisal M, Fylan B, Bristow G, Sohal J, Dalton C . Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study. J Psychopharmacol. 2024; 38(4):382-394. PMC: 11010551. DOI: 10.1177/02698811241238283. View

14.

Lauschke V, Ingelman-Sundberg M . Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. Eur J Pharm Sci. 2019; 130:65-77. DOI: 10.1016/j.ejps.2019.01.024. View

15.

Zhou S . Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009; 48(11):689-723. DOI: 10.2165/11318030-000000000-00000. View

16.

Hu T, Chitnis N, Monos D, Dinh A . Next-generation sequencing technologies: An overview. Hum Immunol. 2021; 82(11):801-811. DOI: 10.1016/j.humimm.2021.02.012. View

17.

Barlati S, Minelli A, Nibbio G, Bertoni L, Necchini N, Paolini S . The role of pharmacogenetics in the treatment of major depressive disorder: a critical review. Front Psychiatry. 2023; 14:1307473. PMC: 10667493. DOI: 10.3389/fpsyt.2023.1307473. View

18.

Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner R . A Review of the Important Role of in Pharmacogenomics. Genes (Basel). 2020; 11(11). PMC: 7692531. DOI: 10.3390/genes11111295. View

19.

Hitchman L, Faatoese A, Merriman T, Miller A, Liau Y, Graham O . Allelic diversity of the pharmacogene CYP2D6 in New Zealand Māori and Pacific peoples. Front Genet. 2022; 13:1016416. PMC: 9606245. DOI: 10.3389/fgene.2022.1016416. View

20.

Qureshi S, Latif A, Condon L, Akyea R, Kai J, Qureshi N . Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis. Pharmacogenomics. 2021; 23(2):135-154. PMC: 8759425. DOI: 10.2217/pgs-2021-0131. View